论文部分内容阅读
Objective: Cyclin-dependent kinase 1 (CDK1) is a master modulator of the initiation and transition process through mammalian mitosis.Previous studies have shown that CDK1activity loss or its aberrant expression are involved in the G2/M phase arrest in many tumor types, and that CDK1 inhibition down regulates survival and induces apoptosis.In addition,CDK1 phosphorylates BRCA1; this is necessary for the ability of CDK1 to efficiently form BRCA1 foci at DNA damage sites and facilitate checkpoint activation.Therefore, CDK1 is considered as an important therapeutic target.It is likely that the reduced CDK1 activity may also sensitize BRCA-proficient tumor cells to PARP inhibition, thereby, facilitating the extension of the synthetic lethal therapeutic option to a larger patient population.